MedTrace Logo

Endovascular Therapy for Acute Basilar Artery Occlusion With Large Ischemic Core

NCT07672795 · Status: NOT_YET_RECRUITING · Phase: NA · Type: INTERVENTIONAL · Enrollment: 256

Last updated 2026-07-02

No results posted yet for this study

Summary

Acute basilar artery occlusion is associated with high mortality and severe disability. Previous randomized trials have demonstrated the benefit of endovascular therapy in selected patients with basilar artery occlusion; however, patients with large ischemic core, commonly defined by low posterior circulation Alberta Stroke Program Early CT Score (pc-ASPECTS), remain underrepresented and the benefit-risk profile of endovascular therapy in this subgroup is uncertain.

This prospective, multicenter, randomized, open-label, blinded-endpoint trial will evaluate the efficacy and safety of endovascular therapy plus best medical management compared with best medical management alone in patients with acute basilar artery occlusion within 24 hours from symptom onset or last known well and pc-ASPECTS \<7. Eligible participants will be randomized in a 1:1 ratio to receive endovascular therapy plus best medical management or best medical management alone. The primary outcome is favorable functional outcome, defined as a modified Rankin Scale score of 0 to 3 at 90 days.

Conditions

  • Acute Ischemic Stroke
  • Basilar Artery Occlusion
  • Large Ischemic Core

Interventions

PROCEDURE

Endovascular Therapy

Endovascular therapy consists of mechanical thrombectomy using stent retriever, direct aspiration, or combined techniques with the goal of achieving rapid and effective reperfusion of the occluded basilar artery.

OTHER

Best Medical Management

Best medical management includes intravenous thrombolysis when eligible, antithrombotic therapy, standard stroke unit care, management of vascular risk factors, blood pressure control, and supportive care according to current clinical guidelines.

Sponsors & Collaborators

  • Dalian Municipal Central Hospital

    collaborator OTHER

  • Linyi People's Hospital

    collaborator OTHER

  • Fujian Zhangzhou hospital

    collaborator UNKNOWN

  • Shanghai Minhang District Central Hospital

    collaborator UNKNOWN

  • The First Affiliated Hospital of University of Science and Technology of China

    lead OTHER

Principal Investigators

  • Wei Hu, PhD · The First Affiliated Hospital of University of Science and Technology of China

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
SINGLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2026-08-01
Primary Completion
2029-07-30
Completion
2029-12-31

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT07672795 on ClinicalTrials.gov